» Articles » PMID: 38203321

Human Precision-Cut Liver Slices: A Potential Platform to Study Alcohol-Related Liver Disease

Abstract

Alcohol-related liver disease (ALD) encompasses a range of pathological conditions that are complex to study at the clinical and preclinical levels. Despite the global burden of ALD, there is a lack of effective treatments, and mortality is high. One of the reasons for the unsuccessful development of novel therapies is that experimental studies are hindered by the challenge of recapitulating this multifactorial disorder in vitro, including the contributions of hepatotoxicity, impaired lipid metabolism, fibrosis and inflammatory cytokine storm, which are critical drivers in the pathogenesis of ALD in patients and primary targets for drug development. Here, we present the unique characteristics of the culture of human precision-cut liver slices (PCLS) to replicate key disease processes in ALD. PCLS were prepared from human liver specimens and treated with ethanol alone or in combination with fatty acids and lipopolysaccharide (FA + LPS) for up to 5 days to induce hepatotoxic, inflammatory and fibrotic events associated with ALD. Alcohol insult induced hepatocyte death which was more pronounced with the addition of FA + LPS. This mixture showed a significant increase in the cytokines conventionally associated with the prototypical inflammatory response observed in severe ALD, and interestingly, alcohol alone exhibited a different effect. Profibrogenic activation was also observed in the slices and investigated in the context of slice preparation. These results support the versatility of this organotypic model to study different pathways involved in alcohol-induced liver damage and ALD progression and highlight the applicability of the PCLS for drug discovery, confirming their relevance as a bridge between preclinical and clinical studies.

Citing Articles

Oxidative stress in a cellular model of alcohol-related liver disease: protection using curcumin nanoformulations.

Petagine L, Zariwala M, Somavarapu S, Chan S, Kaya E, Patel V Sci Rep. 2025; 15(1):7752.

PMID: 40044747 PMC: 11882943. DOI: 10.1038/s41598-025-91139-0.


MetALD: Clinical aspects, pathophysiology and treatment.

Gratacos-Gines J, Arino S, Sancho-Bru P, Bataller R, Pose E JHEP Rep. 2025; 7(2):101250.

PMID: 39897615 PMC: 11782861. DOI: 10.1016/j.jhepr.2024.101250.


In Vivo and In Vitro Models of Hepatic Fibrosis for Pharmacodynamic Evaluation and Pathology Exploration.

Hu Y, Zhang Z, Adiham A, Li H, Gu J, Gong P Int J Mol Sci. 2025; 26(2).

PMID: 39859410 PMC: 11766297. DOI: 10.3390/ijms26020696.


Alcohol-Associated Liver Disease Outcomes: Critical Mechanisms of Liver Injury Progression.

Osna N, Tikhanovich I, Ortega-Ribera M, Mueller S, Zheng C, Mueller J Biomolecules. 2024; 14(4.

PMID: 38672422 PMC: 11048648. DOI: 10.3390/biom14040404.

References
1.
Osna N, Donohue Jr T, Kharbanda K . Alcoholic Liver Disease: Pathogenesis and Current Management. Alcohol Res. 2017; 38(2):147-161. PMC: 5513682. View

2.
Riva A, Palma E, Devshi D, Corrigall D, Adams H, Heaton N . Soluble TIM3 and Its Ligands Galectin-9 and CEACAM1 Are in Disequilibrium During Alcohol-Related Liver Disease and Promote Impairment of Anti-bacterial Immunity. Front Physiol. 2021; 12:632502. PMC: 7987668. DOI: 10.3389/fphys.2021.632502. View

3.
Lamas-Paz A, Hao F, Nelson L, Vazquez M, Canals S, Gomez Del Moral M . Alcoholic liver disease: Utility of animal models. World J Gastroenterol. 2018; 24(45):5063-5075. PMC: 6288648. DOI: 10.3748/wjg.v24.i45.5063. View

4.
Nilsson L, Sjovall J, Strom S, Bodin K, Nowak G, Einarsson C . Ethanol stimulates bile acid formation in primary human hepatocytes. Biochem Biophys Res Commun. 2007; 364(4):743-7. DOI: 10.1016/j.bbrc.2007.10.039. View

5.
van de Bovenkamp M, Groothuis G, Meijer D, Olinga P . Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro. J Hepatol. 2006; 45(5):696-703. DOI: 10.1016/j.jhep.2006.04.009. View